Editorial note: TotalCareMedical.com is an independent health and wellness research publication. We are not a medical practice and do not provide medical advice. This article is an educational overview of known GLP-1 receptor agonist side effects and safety considerations, drawing on published clinical trial data and FDA-approved prescribing information for brand-name GLP-1 medications. Compounded GLP-1 medications dispensed through Refills are not FDA-approved finished drug products. The FDA has not evaluated these compounded medications for safety, quality, or efficacy. Anyone considering GLP-1 therapy should consult a qualified healthcare provider about individual eligibility, contraindications, and risks. This is not medical advice. Individual results vary.
The safety conversation around GLP-1 medications has two layers, and conflating them produces confused consumer reading. The first layer is the side-effect profile of the active molecule itself — semaglutide, tirzepatide — which is well-documented in peer-reviewed clinical trials and in FDA-approved prescribing information for brand-name finished products. The second layer is the regulatory framework around compounded preparations specifically, which is a different conversation about how the medication is prepared and what oversight applies to that preparation.
This article addresses both layers honestly. What the trial data and prescribing information show about how GLP-1 medications act in patients. What contraindications matter. What the FDA compounded disclaimer actually says about safety. And what the patient should be ready to discuss with the evaluating clinician at intake on the Refills GLP-1 program — or any other compounded GLP-1 telehealth platform — to make the clinical evaluation as effective as it can be.
The Side-Effect Profile of GLP-1 Receptor Agonists
The most commonly reported side effects of GLP-1 receptor agonists in clinical trials are gastrointestinal. The mechanism explains the pattern: GLP-1 agonists slow gastric emptying and act on appetite regulation centers, which produces appetite suppression and a feeling of fullness — and which also produces nausea, vomiting, diarrhea, constipation, and abdominal discomfort in a meaningful percentage of patients, especially during early treatment and during dose escalation.
In the STEP-1 trial of semaglutide 2.4 mg published in the New England Journal of Medicine, gastrointestinal side effects were the most commonly reported adverse events. Nausea was reported in roughly 44 percent of participants in the medication arm at some point during the trial. Diarrhea was reported in roughly 32 percent. Constipation in roughly 24 percent. Vomiting in roughly 24 percent. The placebo arm reported all of these symptoms at lower rates, but the symptoms were not absent in the placebo arm — the difference between medication and placebo gives the attributable side-effect picture.
For tirzepatide in the SURMOUNT-1 trial, the gastrointestinal pattern was similar. Nausea was the most commonly reported adverse event. Diarrhea, constipation, and vomiting all appeared at clinically relevant rates. The pattern across the GLP-1 class is consistent: GI effects are the dominant side-effect profile, they tend to be most pronounced during dose escalation, and they tend to attenuate as the body adjusts to a stable dose.
Severity of GI effects varies substantially across patients. Some report mild, transient nausea that resolves within days. Some report more persistent symptoms that take weeks to attenuate. Some report severe enough symptoms that they discontinue therapy. Anyone starting GLP-1 should expect some level of GI adjustment and should have a clear plan with the evaluating clinician for what symptom severity warrants slowing dose escalation, pausing therapy, or contacting the care team.
Less Common but More Serious Risks
Beyond the common GI side-effect profile, GLP-1 prescribing information documents less common but more serious potential risks. These are not features of typical treatment — they are documented possibilities that merit clinical awareness and prompt evaluation if symptoms develop.
Pancreatitis has been reported in association with GLP-1 receptor agonist therapy in post-marketing surveillance and in some clinical observations. The clinical signature is severe abdominal pain, often radiating to the back, frequently with persistent nausea and vomiting beyond what would be expected from typical GI side effects. Patients should be aware of the symptom pattern and should contact a clinician promptly if symptoms consistent with pancreatitis develop. History of pancreatitis is a significant clinical consideration that the evaluating clinician must weigh.
Gallbladder disease — including gallstones and cholecystitis — has been associated with rapid weight loss generally and with GLP-1 therapy specifically. Patients losing weight rapidly are at increased risk of gallstone formation, and GLP-1 therapy can potentiate that risk. Clinical signs include right-upper-quadrant abdominal pain, often after eating fatty meals, and may require imaging and surgical evaluation.
Acute kidney injury has been reported, often in the context of severe dehydration from prolonged vomiting and reduced fluid intake. Maintaining hydration during GLP-1 therapy is clinically important, particularly during dose escalation periods when GI symptoms are most pronounced.
Severe hypoglycemia is a particular consideration for patients also taking insulin or sulfonylureas. GLP-1 alone has a low risk of hypoglycemia in patients without these other agents, but combined with insulin or insulin secretagogues, the risk increases meaningfully and requires clinical adjustment of the other medications.
Allergic reactions, including rare but potentially serious reactions, have been reported. Any sign of allergic reaction — particularly facial swelling, difficulty breathing, or severe rash — warrants immediate medical attention.
Contraindications That Matter
The most clinically significant contraindication for GLP-1 receptor agonists in widespread use is a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The boxed warning in FDA-approved GLP-1 prescribing information is built around this contraindication. The mechanism that drove the warning involves rodent thyroid C-cell tumor findings in preclinical studies; the human clinical relevance is debated but the contraindication is firm in current prescribing.
Patients with a personal or family history of MTC or MEN 2 should not take GLP-1 receptor agonists. This is not a “discuss with your doctor” recommendation; it is a contraindication. Any thoroughgoing intake on a compounded GLP-1 telehealth platform — Refills included — should explicitly screen for MTC and MEN 2 history. If the intake does not screen for this, that is a meaningful red flag about the platform's clinical seriousness.
History of pancreatitis is a significant clinical consideration. Severe gastrointestinal disease, gastroparesis, and certain other GI conditions may also affect candidacy. Pregnancy and lactation are typically considered contraindications or relative contraindications depending on the specific clinical scenario. Severe renal or hepatic impairment may affect dosing or candidacy. The evaluating clinician integrates all of these factors based on the full intake.
For broader weight management context, evidence-based natural strategies covered in our research on natural weight management timelines may serve as a starting point for patients who are not appropriate candidates for pharmacological therapy. Pharmacological intervention is one tool among many, and clinical appropriateness varies.
What the FDA Compounded Disclaimer Actually Means for Safety
Refills states this directly on its website: compounded medications are dispensed by U.S. pharmacies that are highly regulated and inspected by State Boards of Pharmacy, but the FDA has not evaluated these compounded medications for safety, quality, or efficacy. That language is not a footnote and not a formality. It deserves an honest reading.
What it means: the FDA has not run its own review on this specific compounded preparation as a finished product. The agency reviews finished branded drugs through processes like the New Drug Application and ongoing post-marketing surveillance. Compounded preparations made at 503A pharmacies are not subject to those same processes. Compounded preparations made at 503B outsourcing facilities are subject to additional FDA oversight including current Good Manufacturing Practice requirements, but still are not FDA-approved as finished drugs.
What it does not mean: that the medication is unsafe, that the compounding pharmacy is unregulated, or that the active molecule lacks clinical evidence. State Boards of Pharmacy regulate compounding pharmacies including inspections and quality controls. The active molecule (semaglutide, tirzepatide) has substantial peer-reviewed clinical research behind it. Many compounded medications are dispensed safely under appropriate clinical oversight every day.
The honest patient-safety reading: the consumer is buying a state-regulated preparation of a well-studied active molecule, prescribed by a licensed clinician, but not the same finished product the FDA reviewed. The clinician's evaluation, the dispensing pharmacy's quality controls, and ongoing patient monitoring are the safety infrastructure that surrounds any compounded GLP-1 prescription. We cover the structural details of how that infrastructure works in our explainer on compounded semaglutide telehealth.
What to Disclose on Intake
Full disclosure on the intake form supports clinical safety. Items that matter and should be disclosed completely include: full medical history including any chronic conditions; all current prescription medications, over-the-counter medications, and supplements; all known allergies; history of thyroid disease or thyroid cancer in the patient; family history of medullary thyroid carcinoma or MEN 2 syndrome; history of pancreatitis; history of gallbladder disease; history of eating disorders; current pregnancy status or plans for pregnancy; chronic gastrointestinal conditions; history of severe diabetic complications including gastroparesis or proliferative diabetic retinopathy; and any other symptom or condition that might affect medication metabolism or tolerability.
Incomplete disclosure undermines the clinician's ability to evaluate whether GLP-1 therapy is appropriate. The intake is not a sales-funnel form to push through quickly; it is the clinical document the prescriber works from. Treating it accordingly is in the patient's own safety interest.
Monitoring During Treatment
GLP-1 therapy is not a “set and forget” medication. The standard clinical model includes ongoing monitoring during dose escalation and during stable maintenance. Refills' standard program structure includes follow-ups, unlimited clinician access, and required blood work as part of the monthly tier — which is the appropriate monitoring infrastructure for the medication class.
What ongoing monitoring should reasonably cover: tolerance to the current dose, symptom monitoring for any of the more serious risks above, weight and metabolic markers, hydration status, and dose adjustment based on response. The patient's role in monitoring is to report symptoms accurately, follow the dose schedule, maintain hydration, and contact the care team for any symptom that feels unusual or concerning rather than waiting for the next scheduled check-in.
When to Contact a Clinician — and When to Skip Telehealth and Go to the ER
Telehealth messaging is appropriate for non-urgent symptom questions, dose adjustment discussions, and routine monitoring conversations. The Refills platform provides messaging access to the care team for these purposes. The expected response window is documented in the platform terms.
Telehealth is not appropriate for emergent symptoms. Severe abdominal pain especially radiating to the back, signs of severe allergic reaction, signs of severe dehydration with confusion or extreme weakness, severe persistent vomiting, signs of acute hypoglycemia in a patient on insulin, or any other symptom that feels acutely serious should prompt immediate contact with local emergency services or an emergency department rather than waiting for telehealth response.
The honest framing: the telehealth platform is one piece of the patient's safety infrastructure, not the entirety of it. Local emergency care exists for emergencies. Using it appropriately when symptoms are acutely serious is the correct safety behavior.
Who Should Talk to a Different Provider Instead
Some clinical scenarios are better served by traditional in-person care than by any telehealth platform. Patients with complex multi-system medical histories, patients with significant prior GI conditions, patients with diabetes that is poorly controlled or that requires complex insulin management, and patients on multiple chronic medications with known interactions often benefit from in-person evaluation with a primary care physician or endocrinologist who can coordinate the full medication picture.
The convenience of telehealth is real; the limitations are also real. A platform like Refills is structurally well-suited for healthier patients seeking convenient access to a specific therapy. It is structurally less well-suited for patients whose situation requires extensive coordination across providers and systems.
For broader context on the program structure and pricing, see our full Refills GLP-1 review and the Refills GLP-1 pricing breakdown. The category context lives at our Telehealth Platform Reviews hub.
The Final Safety Reading
GLP-1 receptor agonists are evidence-based pharmacological treatments for the patients they're appropriate for. The side-effect profile is well-documented and predominantly gastrointestinal. The serious risks are uncommon but real and warrant clinical awareness and prompt symptom evaluation. The contraindications — particularly MTC and MEN 2 history — are firm and matter.
The compounded preparation regulatory framework is a separate question from the active molecule's pharmacological profile. The FDA disclaimer is substantive but not a verdict that the medication is unsafe. The clinician's evaluation, the dispensing pharmacy's regulation, and ongoing monitoring constitute the safety infrastructure around any compounded GLP-1 prescription.
The honest patient takeaway: GLP-1 therapy can be a meaningful tool for the patients it's right for. Determining whether it's right for any individual patient is a clinical conversation, not a marketing decision. Disclose fully on intake, ask the clinician explicit questions about contraindications relevant to your history, agree on a clear monitoring plan, and use the care team appropriately during treatment. The platform is the delivery mechanism; the clinical relationship is the safety infrastructure. Both have to function for the treatment to function safely.